

## USA, Texas, API (1998-2012)

	Number of cases							Percentage				Incidence rates per million person-years						MV	DCO					
	Age group							0-14		0-19		Age-specific					Cumulative		%	%				
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR	0-19	0-14	0-19	0-19	0-19
I	<b>LEUKAEMIA</b>	8	46	24	20	14	<b>98</b>	<b>112</b>	37.0	100.0	29.2	100.0	38.4	56.6	25.0	22.3	16.0	<b>35.0</b>	<b>30.7</b>	501	581	94.6	1.8	
	a. Lymphoid	3	37	17	9	3	<b>66</b>	<b>69</b>	24.9	67.3	18.0	61.6	14.4	45.5	17.7	10.1	3.4	<b>23.8</b>	<b>19.2</b>	334	352	100.0	0.0	
	b. Acute myeloid	3	7	5	6	4	<b>21</b>	<b>25</b>	7.9	21.4	6.5	22.3	14.4	8.6	5.2	6.7	4.6	<b>7.4</b>	<b>6.8</b>	108	131	100.0	0.0	
	c. CMD	1	0	1	4	3	<b>6</b>	<b>9</b>	2.3	6.1	2.3	8.0	4.8	-	1.0	4.5	3.4	<b>2.0</b>	<b>2.3</b>	32	50	66.7	11.1	
	d. MDS & other	1	1	0	0	2	<b>2</b>	<b>4</b>	0.8	2.0	1.0	3.6	4.8	1.2	-	-	2.3	<b>0.8</b>	<b>1.1</b>	10	21	50.0	0.0	
	e. Unspecified	0	1	1	1	2	<b>3</b>	<b>5</b>	1.1	3.1	1.3	4.5	-	1.2	1.0	1.1	2.3	<b>1.0</b>	<b>1.3</b>	16	27	80.0	20.0	
II	<b>LYMPHOMA &amp; RELATED</b>	1	5	6	14	20	<b>26</b>	<b>46</b>	9.8	100.0	12.0	100.0	4.8	6.1	6.2	15.6	22.8	<b>8.8</b>	<b>12.0</b>	139	253	100.0	0.0	
	a. Hodgkin	0	0	1	8	12	<b>9</b>	<b>21</b>	3.4	34.6	5.5	45.7	-	-	1.0	8.9	13.7	<b>2.9</b>	<b>5.3</b>	50	118	100.0	0.0	
	b. Non-Hodgkin except BL	0	2	2	4	6	<b>8</b>	<b>14</b>	3.0	30.8	3.6	30.4	-	2.5	2.1	4.5	6.8	<b>2.7</b>	<b>3.7</b>	43	77	100.0	0.0	
	c. Burkitt (BL)	0	0	1	1	1	<b>2</b>	<b>3</b>	0.8	7.7	0.8	6.5	-	-	1.0	1.1	1.1	<b>0.7</b>	<b>0.8</b>	11	16	100.0	0.0	
	d. Lymphoreticular	1	3	2	1	1	<b>7</b>	<b>8</b>	2.6	26.9	2.1	17.4	4.8	3.7	2.1	1.1	1.1	<b>2.5</b>	<b>2.2</b>	36	41	100.0	0.0	
	e. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
III	<b>CNS NEOPLASMS †</b>	5	14	20	13	26	<b>52</b>	<b>78</b>	19.6	100.0	20.3	100.0	24.0	17.2	20.8	14.5	29.6	<b>18.1</b>	<b>20.7</b>	270	418	70.5	0.0	
	a. Ependyoma	1	3	0	0	2	<b>4</b>	<b>6</b>	1.5	7.7	1.6	7.7	4.8	3.7	-	-	2.3	<b>1.5</b>	<b>1.7</b>	20	31	100.0	0.0	
	b. Astrocytoma	1	7	7	5	8	<b>20</b>	<b>28</b>	7.5	38.5	7.3	35.9	4.8	8.6	7.3	5.6	9.1	<b>7.0</b>	<b>7.5</b>	103	149	82.1	0.0	
	c. CNS embryonal	2	2	8	2	0	<b>14</b>	<b>14</b>	5.3	26.9	3.6	17.9	9.6	2.5	8.3	2.2	-	<b>4.8</b>	<b>3.8</b>	72	72	100.0	0.0	
	d. Other gliomas	0	2	4	2	2	<b>8</b>	<b>10</b>	3.0	15.4	2.6	12.8	-	2.5	4.2	2.2	2.3	<b>2.7</b>	<b>2.6</b>	42	53	40.0	0.0	
	e. Other specified	0	0	1	3	12	<b>4</b>	<b>16</b>	1.5	7.7	4.2	20.5	-	-	1.0	3.4	13.7	<b>1.3</b>	<b>4.1</b>	22	90	43.8	0.0	
	f. Unspecified CNS	1	0	0	1	2	<b>2</b>	<b>4</b>	0.8	3.8	1.0	5.1	4.8	-	-	1.1	2.3	<b>0.7</b>	<b>1.1</b>	10	22	25.0	0.0	
IV	<b>NEUROBLASTOMA</b>	0	13	3	0	0	<b>16</b>	<b>16</b>	6.0	100.0	4.2	100.0	-	16.0	3.1	-	-	<b>5.9</b>	<b>4.6</b>	79	79	93.8	0.0	
	a. (Ganglio)neuroblastoma	0	13	3	0	0	<b>16</b>	<b>16</b>	6.0	100.0	4.2	100.0	-	16.0	3.1	-	-	<b>5.9</b>	<b>4.6</b>	79	79	93.8	0.0	
	b. Peripheral nervous	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
V	<b>RETINOBLASTOMA</b>	2	2	0	0	0	<b>4</b>	<b>4</b>	1.5	100.0	1.0	100.0	9.6	2.5	-	-	-	<b>1.5</b>	<b>1.2</b>	20	20	75.0	0.0	
VI	<b>RENAL TUMOURS</b>	1	6	1	0	1	<b>8</b>	<b>9</b>	3.0	100.0	2.3	100.0	4.8	7.4	1.0	-	1.1	<b>3.0</b>	<b>2.6</b>	39	45	100.0	0.0	
	a. Nephroblastoma	1	6	1	0	1	<b>8</b>	<b>9</b>	3.0	100.0	2.3	100.0	4.8	7.4	1.0	-	1.1	<b>3.0</b>	<b>2.6</b>	39	45	100.0	0.0	
	b. Renal carcinoma	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	c. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VII	<b>HEPATIC TUMOURS</b>	2	4	2	3	0	<b>11</b>	<b>11</b>	4.2	100.0	2.9	100.0	9.6	4.9	2.1	3.4	-	<b>3.9</b>	<b>3.0</b>	57	57	81.8	0.0	
	a. Hepatoblastoma	2	4	1	0	0	<b>7</b>	<b>7</b>	2.6	63.6	1.8	63.6	9.6	4.9	1.0	-	-	<b>2.6</b>	<b>2.0</b>	35	35	100.0	0.0	
	b. Hepatic carcinoma	0	0	1	3	0	<b>4</b>	<b>4</b>	1.5	36.4	1.0	36.4	-	-	1.0	3.4	-	<b>1.3</b>	<b>1.0</b>	22	22	50.0	0.0	
	c. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VIII	<b>BONE TUMOURS</b>	2	1	3	4	15	<b>10</b>	<b>25</b>	3.8	100.0	6.5	100.0	9.6	1.2	3.1	4.5	17.1	<b>3.4</b>	<b>6.5</b>	53	138	96.0	0.0	
	a. Osteosarcoma	0	0	3	1	8	<b>4</b>	<b>12</b>	1.5	40.0	3.1	48.0	-	-	3.1	1.1	9.1	<b>1.3</b>	<b>3.1</b>	21	67	100.0	0.0	
	b. Chondrosarcoma	0	0	0	0	1	<b>0</b>	<b>1</b>	-	-	0.3	4.0	-	-	-	-	1.1	-	<b>0.3</b>	-	6	6	100.0	0.0
	c. Ewing & related	2	1	0	2	4	<b>5</b>	<b>9</b>	1.9	50.0	2.3	36.0	9.6	1.2	-	2.2	4.6	<b>1.8</b>	<b>2.4</b>	26	49	100.0	0.0	
	d. Other specified	0	0	0	0	1	<b>0</b>	<b>1</b>	-	-	0.3	4.0	-	-	-	-	1.1	-	<b>0.3</b>	-	6	6	100.0	0.0
	e. Unspecified	0	0	0	1	1	<b>2</b>	<b>2</b>	0.4	10.0	0.5	8.0	-	-	-	1.1	1.1	<b>0.3</b>	<b>0.5</b>	6	11	50.0	0.0	
IX	<b>SOFT TISSUE SARCOMA</b>	1	2	1	3	8	<b>7</b>	<b>15</b>	2.6	100.0	3.9	100.0	4.8	2.5	1.0	3.4	9.1	<b>2.4</b>	<b>3.9</b>	37	82	100.0	0.0	
	a. Rhabdomyosarcoma	0	2	0	2	2	<b>4</b>	<b>6</b>	1.5	57.1	1.6	40.0	-	2.5	-	2.2	2.3	<b>1.4</b>	<b>1.6</b>	21	32	100.0	0.0	
	b. Fibrosarcoma	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	c. Kaposi sarcoma	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	d. Other specified	0	0	1	0	3	<b>1</b>	<b>4</b>	0.4	14.3	1.0	26.7	-	-	1.0	-	3.4	<b>0.3</b>	<b>1.0</b>	5	22	100.0	0.0	
	e. Unspecified	1	0	0	1	3	<b>2</b>	<b>5</b>	0.8	28.6	1.3	33.3	4.8	-	-	1.1	3.4	<b>0.7</b>	<b>1.3</b>	10	28	100.0	0.0	
X	<b>GERM CELL TUMOURS</b>	3	3	2	9	12	<b>17</b>	<b>29</b>	6.4	100.0	7.6	100.0	14.4	3.7	2.1	10.1	13.7	<b>5.9</b>	<b>7.6</b>	90	158	96.6	0.0	
	a. CNS germ cell ‡	2	1	1	4	3	<b>8</b>	<b>11</b>	3.0	47.1	2.9	37.9	9.6	1.2	1.0	4.5	3.4	<b>2.8</b>	<b>2.9</b>	42	59	90.9	0.0	
	b. Other extragonadal	0	1	1	1	2	<b>3</b>	<b>5</b>	1.1	17.6	1.3	17.2	-	1.2	1.0	1.1	2.3	<b>1.0</b>	<b>1.3</b>	16	27	100.0	0.0	
	c. Gonadal germ cell	0	1	0	4	5	<b>5</b>	<b>10</b>	1.9	29.4	2.6	34.5	-	1.2	-	4.5	5.7	<b>1.7</b>	<b>2.6</b>	27	56	100.0	0.0	
	d. Gonadal carcinoma	0	0	0	0	2	<b>0</b>	<b>2</b>	-	-	0.5	6.9	-	-	-	-	2.3	-	<b>0.5</b>	-	11	11	100.0	0.0
	e. Unspecified gonadal	1	0	0	0	0	<b>1</b>	<b>1</b>	0.4	5.9	0.3	3.4	4.8	-	-	-	-	<b>0.4</b>	<b>0.3</b>	5	5	100.0	0.0	
XI	<b>CARCINOMA &amp; MELANOMA</b>	0	2	4	8	21	<b>14</b>	<b>35</b>	5.3	100.0	9.1	100.0	-	2.5	4.2	8.9	23.9	<b>4.7</b>	<b>9.0</b>	75	195	100.0	0.0	
	a. Adrenocortical	0	0	1	0	0	<b>1</b>	<b>1</b>	0.4	7.1	0.3	2.9	-	-	1.0	-	-	<b>0.3</b>	<b>0.3</b>	5	5	100.0	0.0	
	b. Thyroid	0	1	0	3	14	<b>4</b>	<b>18</b>	1.5	28.6	4.7	51.4	-	1.2	-	3.4	16.0	<b>1.4</b>	<b>4.6</b>	22	101	100.0	0.0	
	c. Nasopharyngeal	0	0	0	2	2	<b>2</b>	<b>4</b>	0.8	14.3	1.0	11.4	-	-	-	2.2	2.3	<b>0.6</b>	<b>1.0</b>	11	23	100.0	0.0	
	d. Melanoma	0	1	0	0	1	<b>2</b>	<b>2</b>	0.4	7.1	0.5	5.7	-	1.2	-	-	1.1	<b>0.4</b>	<b>0.6</b>	5	11	100.0	0.0	
	e. Skin carcinoma	0	0	1	0	0	<b>1</b>	<b>1</b>	0.4	7.1	0.3	2.9	-	-	1.0	-	-	<b>0.3</b>	<b>0.3</b>	5	5	100.0	0.0	
	f. Other & unspecified	0																						

## USA, Texas, API (1998-2012)

	Males										M/F ratio		Females									
	Number of cases in age groups										0-14	0-19	Number of cases in age groups									
	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19
<b>I LEUKAEMIA</b>	5	30	13	11	10	59	69	41.6	37.2	1.5	1.6	3	16	11	9	4	39	43	28.1	23.9		
a. Lymphoid	1	25	8	4	3	38	41	27.2	22.5	1.4	1.5	2	12	9	5	0	28	28	20.2	15.7		
b. Acute myeloid	2	4	5	5	2	16	18	11.0	9.5	3.2	2.6	1	3	0	1	2	5	7	3.8	4.0		
c. CMD	1	0	0	2	3	3	6	2.0	3.1	1.0	2.0	0	0	1	2	0	3	3	2.0	1.6		
d. MDS & other	1	0	0	0	1	1	2	0.7	1.1	1.0	1.0	0	1	0	0	1	1	2	0.8	1.1		
e. Unspecified	0	1	0	0	1	1	2	0.7	1.1	0.5	0.7	0	0	1	1	1	2	3	1.3	1.6		
<b>II LYMPHOMA &amp; RELATED</b>	0	4	5	9	9	18	27	12.0	13.8	2.3	1.4	1	1	1	5	11	8	19	5.5	10.1		
a. Hodgkin	0	0	1	5	6	6	12	3.8	6.0	2.0	1.3	0	0	0	3	6	3	9	2.0	4.7		
b. Non-Hodgkin except BL	0	1	1	4	3	6	9	4.0	4.6	3.0	1.8	0	1	1	0	3	2	5	1.5	2.7		
c. Burkitt (BL)	0	0	1	0	0	1	1	0.7	0.5	1.0	0.5	0	0	0	1	1	1	2	0.7	1.0		
d. Lymphoreticular	0	3	2	0	0	5	5	3.6	2.8	2.5	1.7	1	0	0	1	1	2	3	1.4	1.6		
e. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>III CNS NEOPLASMS †</b>	3	7	13	8	13	31	44	21.1	22.8	1.5	1.3	2	7	7	5	13	21	34	15.0	18.5		
a. Ependymoma	1	2	0	0	1	3	4	2.2	2.2	3.0	2.0	0	1	0	0	1	1	2	0.8	1.1		
b. Astrocytoma	0	2	4	3	5	9	14	6.0	7.2	0.8	1.0	1	5	3	2	3	11	14	8.0	7.8		
c. CNS embryonal	1	2	5	1	0	9	9	6.2	4.8	1.8	1.8	1	0	3	1	0	5	5	3.5	2.7		
d. Other gliomas	0	1	3	2	1	6	7	4.0	3.6	3.0	2.3	0	1	1	0	1	2	3	1.5	1.7		
e. Other specified	0	0	1	2	5	3	8	1.9	4.0	3.0	1.0	0	0	0	1	7	1	8	0.7	4.2		
f. Unspecified CNS	1	0	0	0	1	1	2	0.7	1.1	1.0	1.0	0	0	0	1	1	1	2	0.7	1.0		
<b>IV NEUROBLASTOMA</b>	0	7	2	0	0	9	9	6.5	5.1	1.3	1.3	0	6	1	0	0	7	7	5.3	4.1		
a. (Ganglio)neuroblastoma	0	7	2	0	0	9	9	6.5	5.1	1.3	1.3	0	6	1	0	0	7	7	5.3	4.1		
b. Peripheral nervous	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>V RETINOBLASTOMA</b>	1	1	0	0	0	2	2	1.5	1.2	1.0	1.0	1	1	0	0	0	2	2	1.5	1.2		
<b>VI RENAL TUMOURS</b>	1	4	0	1	5	6	6	3.7	3.4	1.7	2.0	0	2	1	0	0	3	3	2.2	1.7		
a. Nephroblastoma	1	4	0	0	1	5	6	3.7	3.4	1.7	2.0	0	2	1	0	0	3	3	2.2	1.7		
b. Renal carcinoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>VII HEPATIC TUMOURS</b>	0	3	1	1	0	5	5	3.5	2.7	0.8	0.8	2	1	1	2	0	6	6	4.3	3.3		
a. Hepatoblastoma	0	3	1	0	0	4	4	2.9	2.2	1.3	1.3	2	1	0	0	0	3	3	2.3	1.8		
b. Hepatic carcinoma	0	0	0	1	0	1	1	0.6	0.5	0.3	0.3	0	0	1	2	0	3	3	2.0	1.6		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>VIII BONE TUMOURS</b>	1	0	2	2	7	5	12	3.3	6.1	1.0	0.9	1	1	1	2	8	5	13	3.5	7.0		
a. Osteosarcoma	0	0	2	1	3	3	6	2.0	3.0	3.0	1.0	0	0	1	0	5	1	6	0.7	3.2		
b. Chondrosarcoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.5		
c. Ewing & related	1	0	0	1	4	2	6	1.4	3.1	0.7	2.0	1	1	0	1	0	3	3	2.2	1.7		
d. Other specified	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.5		
e. Unspecified	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	1	1	2	0.7	1.0		
<b>IX SOFT TISSUE SARCOMA</b>	0	2	1	2	6	5	11	3.4	5.6	2.5	2.8	1	0	0	1	2	2	4	1.4	2.2		
a. Rhabdomyosarcoma	0	2	0	2	0	4	4	2.8	2.1	-	2.0	0	0	0	0	2	0	2	-	1.1		
b. Fibrosarcoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
d. Other specified	0	0	1	0	3	1	4	0.7	2.0	-	-	0	0	0	0	0	0	0	-	-		
e. Unspecified	0	0	0	0	3	0	3	-	1.5	0.0	1.5	1	0	0	1	0	2	2	1.4	1.1		
<b>X GERM CELL TUMOURS</b>	2	1	0	5	8	8	16	5.4	8.2	0.9	1.2	1	2	2	4	4	9	13	6.3	7.0		
a. CNS germ cell ‡	1	0	0	4	3	5	8	3.3	4.0	1.7	2.7	1	1	1	0	0	3	3	2.2	1.7		
b. Other extragonadal	0	0	0	1	2	1	3	0.6	1.5	0.5	1.5	0	1	1	0	0	2	2	1.5	1.1		
c. Gonadal germ cell	0	1	0	0	3	1	4	0.7	2.1	0.3	0.7	0	0	0	4	2	4	6	2.6	3.1		
d. Gonadal carcinoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	2	0	2	-	1.1		
e. Unspecified gonadal	1	0	0	0	0	1	1	0.7	0.6	-	-	0	0	0	0	0	0	0	-	-		
<b>XI CARCINOMA &amp; MELANOMA</b>	0	1	1	5	4	7	11	4.6	5.5	1.0	0.5	0	1	3	3	17	7	24	4.8	12.7		
a. Adrenocortical	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	1	0	0	1	1	0.7	0.5		
b. Thyroid	0	0	0	2	1	2	3	1.3	1.5	1.0	0.2	0	1	0	1	13	2	15	1.4	8.0		
c. Nasopharyngeal	0	0	0	2	2	2	4	1.3	2.0	-	-	0	0	0	0	0	0	0	-	-		
d. Melanoma	0	1	0	0	0	1	1	0.7	0.6	-	1.0	0	0	0	0	1	0	1	-	0.5		
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	1	0	0	1	1	0.7	0.5		
f. Other & unspecified	0	0	1	1	1	2	3	1.3	1.5	0.7	0.5	0	0	1	2	3	3	6	2.0	3.1		
<b>XII OTHER &amp; UNSPECIFIED</b>	0	1	0	0	1	1	2	0.7	1.1	1.0	1.0	0	1	0	0	1	1	2	0.8	1.1		
a. Other specified	0	1	0	0	0	1	1	0.7	0.6	-	1.0	0	0	0	0	1	0	1	-	0.5		
b. Other unspecified	0	0	0	0	1	0	1	-	0.5	0.0	1.0	0	1	0	0	0	1	1	0.8	0.6		
<b>TOTAL</b>	13	61	38	43	59	155	214	107.5	112.7	1.4	1.3	12	39	28	31	60	110	170	79.0	92.9		

† includes 10 non-malignant in males and 10 non-malignant in females ‡ includes 1 non-malignant in females

Please consult the quality indicators for this registry

## USA, Texas, API (1998-2012)

	Age group	Males	Females
Person-years	0	107 442	100 812
	1-4	413 631	399 771
	5-9	487 118	474 579
	10-14	455 896	439 199
	15-19	452 430	425 201
Total	0-14	1 464 087	1 414 361
	0-19	1 916 517	1 839 562
Average annual population	0-14	97 606	94 291
	0-19	127 768	122 637

Please consult the quality indicators for this registry